Drug Testing Locations in Texas

Accredited Drug Testing has 1,643 drug testing centers in 2,696 TX cities.

Please select a city from the list below to find drug test centers in Texas.

Essential Drug Testing for Texas Employers

For Texas employers, ensuring a drug-free workplace is crucial, and our services are designed to meet these needs with utmost efficiency. With 1,645 centers located in 2,698 cities, our reach makes drug testing accessible, reliable, and timely, ensuring compliance and safety.

Our comprehensive testing services help mitigate risks associated with drug use in the workplace, fostering a safer, more productive environment. The extensive network within Texas allows employers to streamline their drug testing processes, saving time and resources.

The accuracy and promptness of our services equip employers with the necessary tools to maintain workplace integrity and safety standards. With diverse testing options, our solutions cater to varied industry requirements, ensuring each business receives tailored support.

Moreover, our user-friendly approach and professional expertise provide clarity and support throughout the process, making us a trusted partner for workplace health and safety.

Texas Drug Free Workplace Programs

While Texas does not have a formal statewide Drug Free Workplace Program, it actively promotes a healthy work environment through various initiatives. Many private companies within Texas voluntarily implement drug-free policies, fostering safer and more productive workplaces. These measures are pivotal in reducing workplace accidents and ensuring employee well-being.

Community outreach and educational programs play a significant role in mitigating substance misuse. By partnering with local organizations, Texas raises awareness about the harmful effects of drugs, offering support and resources to employers and employees alike. These collective efforts help maintain safety and productivity, contributing to a healthier state workforce.

How does the body eliminate Drugs

Drug elimination is the sum of the processes of removing an administered drug from the body. In the pharmacokinetic ADME scheme (absorption, distribution, metabolism, and excretion), it is frequently considered to encompass both metabolism and excretion. Hydrophobic drugs, to be excreted, must undergo metabolic modification making them more polar. Hydrophilic drugs, on the other hand, can undergo excretion directly, without the need for metabolic changes to their molecular structures.

Although many sites of metabolism and excretion exist, the chief organ of metabolism is the liver, while the organ primarily tasked with excretion is the kidney. Any significant dysfunction in either organ can result in the accumulation of the drug or its metabolites in toxic concentrations.

A variety of other factors impact elimination — intrinsic drug properties, such as polarity, size, or pKa. Also other factors include genetic variation among individuals, disease states affecting other organs, and pathways involved in the way the drug distributes through the body, such as first-pass metabolism.

Issues of Concern

Drug elimination is the removal of an administered drug from the body. It is accomplished in two ways, either by excretion of an unmetabolized drug in its intact form or by metabolic biotransformation followed by excretion. While excretion is primarily carried out by the kidneys, other organ systems are involved as well. Similarly, the liver is the primary site of biotransformation, yet extrahepatic metabolism takes place in a variety of organ systems affecting multiple drugs.

Given the multiple organ systems and the variety of metabolic transformations present, drug elimination can entail a significant degree of complexity. Hydrophilic drugs are typically directly excreted by the kidneys, while hydrophobic drugs undergo biotransformation before excretion. The purpose here is twofold – biotransformation serves both detoxify the exogenous substances as well as to increase their hydrophilicity, ensuring their elimination via the kidneys.

Two broad metabolic pathways of hepatic drug transformation exist. Phase I is the direct modification of the target molecule, whereas phase II entails conjugation of the target to a polar molecule of low molecular weight. Phase I prepare the drug to enter phase II, but single-phase metabolism also exists.

Phase I involves oxidation, reduction, and hydrolysis of the exogenous molecule. These reactions are accomplished by hepatic microsomal enzymes, which reside in the smooth endoplasmic reticulum of the hepatocytes. Best known among them is the cytochrome P450 system, whose enzymes are predominantly involved in oxidative metabolism. Within the cytochrome P450 family (CYP), the enzyme responsible for the metabolism of more than 50% of existing drugs is the CYP3A4. Its activity encompasses various classes of medications, including opioids, immunosuppressants, antihistamines, and benzodiazepines. The enzymes can also be induced or inhibited by a variety of substances they interact with, including pharmaceuticals. The increase in metabolic activity with CYP induction results in a diminished activity of drugs targeted by that particular isoform. Conversely, CYP inhibition will result in increased drug plasma concentration, potentially leading toxicity. The CYP3A4 is induced by phenytoin, phenobarbital, and St. John's wort, while diltiazem, erythromycin, and grapefruit inhibit it. Caution is, therefore, necessary when administering CYP3A4-metabolized drugs in the presence of any of the inhibitors or inducers.

Phase II consists of covalent bonding of polar groups to nonpolar molecules to render them water-soluble and allow renal or biliary excretion. Target molecules enter phase II directly or via initial processing through phase I. A variety of polar adjuncts is transferred, including amino acids, glucuronic acid, glutathione, acetate, and sulfate. Glucuronidation is one of the major pathways of phase II biotransformation. The UDP-glucuronosyltransferase (UGT) enzyme family performs this activity. Typically, glucuronide derivatives possess less or no activity of the original drug, but in some cases, pharmacologically active compounds result. Morphine-6-glucuronide is a phase II metabolite of morphine with significant analgesic activity. As with the CYP enzymes, inducers, and inhibitors of phase II, enzymes exist and may influence the efficacy of drugs that rely on conjugation before excretion.

The first-pass effect is a feature of hepatic metabolism that also plays a role in the elimination of multiple drugs. Here, the enteric consumed drugs are exposed directly to the liver via the portal vein, where they undergo biotransformation before entering the systemic circulation. This activity reduces the bioavailability and needs to be factored into the dose administered to the patient. Intravenously administered drugs are not subject to the first-pass effect.

Extrahepatic drug metabolism takes place in the GI tract, kidneys, lungs, plasma, and skin.

Renal excretion completes the process of elimination that begins in the liver. Polar drugs or their metabolites get filtered in the kidneys and typically do not undergo reabsorption. They subsequently get excreted in the urine. Urinary pH has a significant impact on excretion, as drug ionization changes depending on the alkaline or acidic environment. Increased excretion occurs with weakly acidic drugs in basic urine and weakly basic drugs in acidic urine.

Excretion in the bile is another significant form of drug elimination. The liver can actively secrete ionized drugs with a molecular weight greater than 300 g/mol into bile, from where they reach the digestive tract and are either eliminated in feces or reabsorbed as part of the enterohepatic cycle.

Other pathways of excretion include the lungs, breast milk, sweat, saliva, and tears

Mobile/On-Site Drug Testing

If you're an employer needing to test 25 or more employees and looking to save time and money, we offer mobile on-site drug testing where we come to you. Call us today for more information.

Texas Laws on Drugs

In Texas, drug laws are stringent, focusing on control and prevention to maintain public safety. The Texas Controlled Substances Act regulates the possession, distribution, and manufacturing of controlled substances, ensuring strict penalties for violations based on factors such as type and quantity of drug.

Penalties can range from fines to imprisonment, depending on the severity of the offense. Texas emphasizes a strong legal framework to discourage drug-related activities, promoting awareness and intervention to reduce the incidence of illegal drug use and its impacts on communities.

Texas Laws on Marijuana

In Texas, marijuana laws are particularly restrictive. Marijuana remains illegal for recreational use, with possession potentially resulting in severe legal consequences, including fines and incarceration. Efforts focus on discouraging its use, despite changing perspectives in other states.

For medical use, Texas has a limited compassionate use program permitting low-THC cannabis for specific medical conditions. Any broader legalization or decriminalization remains a contentious topic, with ongoing debates about potential economic and social impacts.

Texas Drug Resources

Texas Drug Testing
Provides extensive drug testing services statewide.

Texas Health and Human Services
Offers addiction treatment and prevention resources.

National Safety Council
Provides workplace safety training including drug testing.

SAMHSA
Locate treatment centers and get substance abuse help.

NIDA
Find research and resources on drug abuse and prevention.

Texas Tribune Drug Coverage
Read the latest drug policy news and updates.

Texas Attorney General
Information on legal consequences of drug offenses.

Drug Testing Near , TX

Frequently Asked Questions

Customer Reviews